Melanocortin research comparison

PT-141 vs Melanotan II: related chemistry, different evidence

An educational comparison of bremelanotide and Melanotan II: how the compounds are related, why their names are not interchangeable, and what labels, trials, and case reports can actually show.

Educational guideUpdated August 29, 2026

How to read the evidence without mixing the products

Identify the exact compound: bremelanotide, Vyleesi, and Melanotan II are not interchangeable names for one product.

Identify the evidence source: prescribing information, a controlled trial, a chemical analysis, a case report, or a personal anecdote answers a different question.

Use case reports correctly: they can reveal a possible safety signal, but they cannot estimate how often it occurs or establish cause on their own.

Keep pigmentation effects in context: a biological effect on pigment is not evidence of safe tanning or protection from ultraviolet damage.

Avoid cross-product conclusions: evidence for a labeled bremelanotide product does not establish the identity, safety, or effect of Melanotan II.

Direct answer

PT-141 and Melanotan II arose from related melanocortin research, but they are different compounds and their evidence cannot be exchanged. PT-141 usually refers to bremelanotide; Vyleesi is a specific FDA-approved bremelanotide product with a narrow indication and formal labeling. Melanotan II has no FDA-approved finished drug product, and much of its human safety record comes from reports involving unregulated tanning or libido products rather than controlled treatment trials. Peptide12 does not offer, prescribe, compound, sell, or facilitate access to Melanotan II; this page explains product identity and evidence quality without dosing or access guidance.

Product identity

PT-141 usually means bremelanotide; Melanotan II is not Vyleesi

Bremelanotide was developed from melanocortin research, so PT-141 and Melanotan II may appear together in searches and peptide forums. That relationship does not make the names, products, evidence, or regulatory status interchangeable. The current Vyleesi label identifies a specific bremelanotide injection for acquired, generalized HSDD in premenopausal women when low desire causes marked distress or interpersonal difficulty and is not better explained by another condition, relationship issue, medicine, or substance. Melanotan II products sold for tanning or libido do not inherit that approval.

Vyleesi is not indicated for men, postmenopausal women, erectile dysfunction, or sexual-performance enhancement.
A compounded bremelanotide preparation is not the same FDA-approved finished product as Vyleesi; identity, formulation, evidence, and labeling remain product-specific.
A vial or nasal spray labeled Melanotan II, “MT2,” “research use only,” or “tanning peptide” should not be represented as prescription bremelanotide or as FDA-approved because both affect melanocortin pathways.

Reading safety evidence

Labels and case reports answer different questions

Vyleesi labeling summarizes evidence collected for a defined bremelanotide product and includes blood-pressure, heart-rate, nausea, and focal-hyperpigmentation information. Melanotan II reports describe different and often poorly characterized exposures from unregulated injections or nasal products. Published case reports have described priapism, renal infarction, and concerning oral or skin pigmentation after reported use. Those reports can identify questions worth investigating, but they cannot establish frequency, causation, or a complete safety profile.

PT-141 should not be marketed as a tanning product. The Vyleesi hyperpigmentation warning is an adverse-effect consideration, not evidence of a safe cosmetic-tanning benefit.
A prolonged erection lasting four hours or longer needs emergency evaluation. Chest pain, fainting, severe headache with neurologic symptoms, severe allergic symptoms, or rapidly worsening illness also need urgent care.
A new, changing, bleeding, asymmetric, unusually colored, or otherwise concerning skin or oral lesion should be assessed by an appropriate clinician; do not use more peptide to “even out” pigmentation or delay dermatology or dental evaluation.

Evidence limits

Case reports can identify red flags but cannot create a treatment protocol

The Melanotan II literature includes public-health commentary, product-identification work, and individual adverse-event reports. Those sources help explain uncertainty around product identity and potential harm, but they do not establish a standardized, quality-controlled product, a safe nasal or injectable amount, long-term tanning safety, or superiority for libido. Vyleesi evidence and labeling also cannot be transferred to Melanotan II. There are no reliable head-to-head data showing that one should be substituted for the other.

Do not compare outcomes across a labeled bremelanotide program, a Melanotan II case report, social-media photos, or seller testimonials as though they were equivalent trials.
An apparent lack of an immediate reaction does not confirm purity, sterility, identity, cardiovascular safety, kidney safety, or long-term skin safety.
Tanning does not protect against ultraviolet injury. A product that darkens pigment should not be treated as sunscreen or a substitute for sun-protection and skin-cancer screening advice.

Interpreting claims

A shared pathway does not create shared evidence

Because both names appear in melanocortin research, online summaries sometimes blur PT-141, Vyleesi, and Melanotan II. Pharmacologic relationship is useful for understanding the history of the molecules, but it does not make one compound a substitute for another or transfer the evidence from a finished drug to an online vial or nasal spray. Every claim must stay attached to the exact substance, formulation, population, route, and outcome that were actually studied.

“MT2 is the same as PT-141” and “Vyleesi proves Melanotan II works” both collapse important identity and evidence differences.
Photos, testimonials, and a visible pigment change do not measure ultraviolet protection, long-term skin outcomes, or product identity.
This page does not translate case reports or bremelanotide labeling into a Melanotan II dose, protocol, or combination guide.

Research-reading checklist

Questions for reading PT-141 and Melanotan II claims

Use these questions to assess the quality and limits of public research. This page does not recommend or facilitate use of an unapproved substance.

✓

Does the source distinguish bremelanotide, the Vyleesi finished product, and Melanotan II by exact name?

✓

Is the claim based on controlled human evidence, product labeling, chemical testing, a case report, or an anecdote?

✓

Does the formulation and route in the claim match what the cited source actually studied?

✓

Is a case report being used to flag a possible event, or incorrectly presented as proof of frequency or causation?

✓

Is a pigmentation effect being confused with safe tanning, ultraviolet protection, or a cosmetic benefit?

✓

Are adverse observations reported with the same clarity as desired effects and testimonials?

✓

Does the comparison avoid transferring Vyleesi findings or approval to Melanotan II?

✓

Does the source avoid dose charts, stacks, access instructions, guarantees, and treatment recommendations for Melanotan II?

FAQs

Short evidence answers

Are PT-141 and Melanotan 2 the same peptide?

No. PT-141 usually refers to bremelanotide, while Melanotan II is a different melanocortin analog commonly promoted online for tanning or libido. They are historically and pharmacologically related, but their product identity, evidence, labeling, and safety context are not interchangeable.

Is Melanotan II FDA-approved because Vyleesi is approved?

No. FDA approval is product- and indication-specific. The approved Vyleesi label applies to its bremelanotide product and narrow HSDD indication. It does not approve Melanotan II tanning injections, nasal sprays, research products, or peptide blends.

Does PT-141 safely make you tan?

PT-141 should not be used or sold as a tanning treatment. Vyleesi labeling warns about focal hyperpigmentation in some patients, but an adverse pigmentation effect is not proof of a safe, even, or protective tan. Discuss unexpected pigmentation and any changing lesion with an appropriate clinician.

Do the available studies show Melanotan II is a safer alternative to PT-141?

No. There is no suitable head-to-head evidence supporting that conclusion. The two compounds have different product contexts and evidence bases, so neither online anecdotes nor separate studies can establish a comparative safety ranking.

Has combining PT-141 and Melanotan II been established in controlled trials?

No suitable controlled evidence cited here establishes a combination treatment, dose, or schedule. A seller-created stack is not clinical evidence, and this page provides no combination instructions.

What seller claims should I avoid?

Avoid “FDA-approved tanning peptide,” “MT2 is Vyleesi,” no-prescription PT-141, research-use products marketed to people, universal tanning or libido doses, guaranteed results, unlabeled blends, missing pharmacy identity, and advice to ignore blood-pressure symptoms, prolonged erection, or changing skin lesions.

Sources and related reading

Primary regulatory sources and complete study reports provide the clearest context for research-stage substances.

DailyMed: current Vyleesi (bremelanotide) prescribing information MedlinePlus: Bremelanotide injection drug information PubMed: Melanotan tanning injection and priapism case report PubMed: Melanotan II and renal infarction case report and literature review PubMed: Unregulated Melanotan II use and Australian dermatology public-health concerns PubMed: Melanotan II nasal spray and possible oral mucosal melanoma risk report Peptide12: PT-141 bremelanotide online guide Peptide12: PT-141 vs Vyleesi product identity Peptide12: PT-141 and blood pressure Peptide12: PT-141 medication interactions Peptide12: PT-141 dosing-chart red flags Peptide12: PT-141 side effects Peptide12: Sexual health guide